Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis.

No abstract is available for this paper.

• Publication year

  1983

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  1983-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1136/jnnp.46.5.383PMID 6101172PMCID PMC1027383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. I. Receptor degradation.

  1983cited by this paper
• Mechanisms of acetylcholine receptor loss from the neuromuscular junction.

  1982cited by this paper
• Denervation accelerates the degradation of junctional acetylcholine receptors.

  1981cited by this paper
• Denervated endplates have a dual population of junctional acetylcholine receptors

  1981cited by this paper
• Antibodies from myasthenic patients that compete with cholinergic agents for binding to nicotinic receptors.

  1980cited by this paper
• Neuromuscular transmission.

  1979cited by this paper
• Ultrastructural Localization of the Terminal and Lytic Ninth Complement Component (C9) at the Motor End‐plate in Myasthenia Gravis

  1979cited by this paper
• Biosynthesis and degradation of acetylcholine receptors in rat skeletal muscles. Effects of electrical stimulation.

  1979cited by this paper
• Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions.

  1978cited by this paper
• Antibody to acetylcholine receptor increases degradation of junctional and extrajunctional receptors in adult muscle

  1978cited by this paper
• Effect of myasthenic patients' immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process.

  1978cited by this paper
• Myasthenia gravis serum reduces acetylcholine sensitivity in cultured rat myotubes

  1977cited by this paper
• Human myasthenic sera reduce acetylcholine sensitivity of human muscle cells in tissue culture

  1977cited by this paper
• Modulation of acetylcholine receptor by antibody against the receptor.

  1977cited by this paper

• The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?

  2025cites this paper
• ANTIBODIES AND RECEPTORS: from neuromuscular junction to central nervous system.

  2020cites this paper
• John Newsom-Davis. 18 October 1932—24 August 2007

  2019cites this paper
• Cellular, synaptic, and circuit effects of antibodies in autoimmune CNS synaptopathies.

  2016cites this paper
• Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

  2015cites this paper
• [Plasmapheresis and immunoglobulin therapy].

  2012cites this paper
• FUNCTIONAL PLASTICITY OF HIPPOCAMPAL GLUTAMATERGIC SYNAPSES IN DEVELOPMENT AND DISEASE

  2011cites this paper
• Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies

  2010cites this paper
• Autoimmune disorders of the neuromuscular junction.

  2009cites this paper
• Autoimmune disorders of the neuromuscular junction.

  2008cites this paper
• Therapy of myasthenia gravis.

  2008cites this paper
• 31 – Autoimmune and Genetic Disorders of the Neuromuscular Junction and Motor Nerve Terminal

  2007cites this paper
• Myasthenia Gravis and other Antibody-Associated Neurological Diseases

  2006cites this paper
• Autoimmune channelopathies and related neurological disorders.

  2006cites this paper
• Mechanisms in myasthenia gravis

  2005cites this paper
• Effect of estradiol and progesterone on muscle weight and acetylcholine receptors in “myasthenic” rats

  2005cites this paper
• Immunotherapy in autoimmune neuromuscular disorders.

  2003cites this paper
• Molecular targets for autoimmune and genetic disorders of neuromuscular transmission.

  2000cites this paper
• Disorders of the Human Neuromuscular Junction

  1997cites this paper
• Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis.

  1996cites this paper
• Antibodies to Acetylcholine Receptors in Myasthenia Gravis

  1989cites this paper
• Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect.

  1988cites this paper
• Disorders of Cholinergic Synapses in the Peripheral Nervous System

  1988cites this paper
• Disorders affecting the acetylcholine receptor: myasthenia gravis and congenital myasthenia.

  1987cites this paper
• Humoral Pathogenesis of Myasthenia Grayis a

  1987cites this paper
• Decrease in acetylcholine-receptor content of human myotube cultures mediated by monoclonal antibodies to alpha, beta and gamma subunits.

  1986cites this paper
• Decrease in acetylcholine‐receptor content of human myotube cultures mediated by monoclonal antibodies to α, β and γ subunits

  1986cites this paper
• Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome.

  1985cites this paper
• Nicotinic acetylcholine receptors in vertebrate muscle: properties, distribution and neural control.

  1985cites this paper
• Myasthenia gravis and myasthenic syndromes

  1984cites this paper
• Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. I. Receptor degradation.

  1983cites this paper